Jin Xu
Family Medicine · Seattle, WANPI 1215990080
Payments from drug & device makers
Across 405 payments — averaging $15.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$961
- AstraZeneca$750
- Boehringer Ingelheim$533
- GSK$452
- Lilly USA, LLC$444
- plus $2K from 19 others
What the payments were for
- Food & beverage$6,18599%
- Education$331%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 76 | $1,258 |
| Novo Nordisk | 60 | $961 |
| AstraZeneca | 47 | $750 |
| Boehringer Ingelheim | 37 | $533 |
| GSK | 34 | $452 |
| Lilly USA, LLC | 29 | $444 |
| Pfizer | 28 | $370 |
| Merck | 23 | $299 |
| Amarin Pharma, Inc. | 17 | $227 |
| Johnson & Johnson | 15 | $210 |
| Novartis | 8 | $152 |
| Amgen | 6 | $106 |
| Kowa Pharmaceuticals America, Inc. | 6 | $80 |
| Medtronic | 1 | $80 |
| Sanofi-aventis U.S. LLC | 5 | $71 |
| Bayer | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Biohaven Pharmaceuticals, Inc. | 2 | $31 |
| Eisai Inc. | 1 | $21 |
| Shire North American Group Inc | 1 | $20 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $20 |
| Abbott | 1 | $19 |
| Amneal Pharmaceuticals LLC | 1 | $16 |
| Aytu Biopharma, Inc. | 1 | $14 |
| Scilex Pharmaceuticals Inc. | 1 | $12 |
How this compares
$6,217 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 26 | $18,486 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,276 |
| Atorvastatin Calcium | 167 | $1,791 |
| SynthroidLevothyroxine Sodium | 16 | $1,415 |
| Omeprazole | 97 | $1,150 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 16 | $939 |
| Metoprolol Succinate | 58 | $901 |
| Rosuvastatin Calcium | 34 | $863 |
| Duloxetine Hcl | 18 | $860 |
| Levothyroxine Sodium | 68 | $850 |
| Valsartan | 20 | $720 |
| Simvastatin | 75 | $696 |
| Montelukast Sodium | 30 | $598 |
| Sertraline Hcl | 56 | $567 |
| Amlodipine Besylate | 79 | $511 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $533 | $18,48626 claims |
| GSKTrelegy Ellipta | $452 | $12,27617 claims |
| AbbVieSynthroid | $1,258 | $1,41516 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $16 | $85068 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Seattle
- Emily ZaragozaSeattle$1.9M
- Kevin HatfieldSeattle$527K
- Michelle KarunaSeattle$271K
- Robert McIntyreSeattle$107K
- Emily GodfreySeattle$98K
- Christopher ShuhartSeattle$56K
- Ian BennettSeattle$41K
- Betsy BrownSeattle$23K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.